These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17695658)

  • 1. Niacin plus statin: powerful anti-cholesterol partnership. Use of the B vitamin niacin may help keep your cholesterol under control, but there are certain things you should know before starting therapy.
    Heart Advis; 2007 Jul; 10(7):9. PubMed ID: 17695658
    [No Abstract]   [Full Text] [Related]  

  • 2. Avoid no-flush niacin in favor of the prescription version. Follow certain steps to reduce the flushing effects of prescription niacin.
    Heart Advis; 2010 Nov; 13(11):5. PubMed ID: 22834056
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and tolerability of extended-release niacin with laropiprant.
    Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
    Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niacin: its value in raising HDL cholesterol is being questioned.
    Heart Advis; 2011 Oct; 14(10):7. PubMed ID: 23019714
    [No Abstract]   [Full Text] [Related]  

  • 5. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
    Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niacin, an old drug with new perspectives for the management of dyslipidaemia.
    Benhalima K; Muls E
    Acta Clin Belg; 2010; 65(1):23-8. PubMed ID: 20373594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
    Paolini JF; Bays HE; Ballantyne CM; Davidson M; Pasternak R; Maccubbin D; Norquist JM; Lai E; Waters MG; Kuznetsova O; Sisk CM; Mitchel YB
    Cardiol Clin; 2008 Nov; 26(4):547-60. PubMed ID: 19031552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
    McKenney J; Bays H; Koren M; Ballantyne CM; Paolini JF; Mitchel Y; Betteridge A; Kuznetsova O; Sapre A; Sisk CM; Maccubbin D
    J Clin Lipidol; 2010; 4(2):105-112.e1. PubMed ID: 21122637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More on niacin: no flush, no good.
    Harv Health Lett; 2007 Jul; 32(9):7. PubMed ID: 17663076
    [No Abstract]   [Full Text] [Related]  

  • 10. Elevating your HDL game. "Good" cholesterol levels can be increased in several ways, but taking niacin is the most effective.
    Harv Health Lett; 2010 Jul; 35(9):6-7. PubMed ID: 20821856
    [No Abstract]   [Full Text] [Related]  

  • 11. A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
    Jacobson TA
    Mayo Clin Proc; 2010 Apr; 85(4):365-79. PubMed ID: 20360295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.
    Yadav R; France M; Younis N; Hama S; Ammori BJ; Kwok S; Soran H
    Expert Opin Pharmacother; 2012 Jun; 13(9):1345-62. PubMed ID: 22607011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia.
    Thakkar RB; Kashyap ML; Lewin AJ; Krause SL; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2009; 9(2):69-79. PubMed ID: 19331435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation.
    Cefali EA; Simmons PD; Stanek EJ; Shamp TR
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):633-40. PubMed ID: 17190373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin into the void. Failure of HDL cholesterol drug may B this vitamin's big chance.
    Harv Health Lett; 2007 Apr; 32(6):6. PubMed ID: 17390509
    [No Abstract]   [Full Text] [Related]  

  • 16. The mechanism and mitigation of niacin-induced flushing.
    Kamanna VS; Ganji SH; Kashyap ML
    Int J Clin Pract; 2009 Sep; 63(9):1369-77. PubMed ID: 19691622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy.
    Rhodes T; Norquist JM; Sisk CM; McQuarrie K; Trovato A; Liao J; Miller T; Maccubbin D; Watson DJ
    Int J Clin Pract; 2013 Dec; 67(12):1238-46. PubMed ID: 24102896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New thinking on niacin use. Using niacin to raise "good" cholesterol doesn't lower your risk of having a heart attack or stroke.
    Harv Health Lett; 2014 Aug; 39(10):6. PubMed ID: 25230410
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Shah S; Ceska R; Gil-Extremera B; Paolini JF; Giezek H; Vandormael K; Mao A; McCrary Sisk C; Maccubbin D
    Int J Clin Pract; 2010 May; 64(6):727-38. PubMed ID: 20518948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a questionnaire to assess niacin-induced cutaneous flushing.
    Norquist JM; Watson DJ; Yu Q; Paolini JF; McQuarrie K; Santanello NC
    Curr Med Res Opin; 2007 Jul; 23(7):1549-60. PubMed ID: 17559750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.